Infliximab Effectiveness Remained High Despite Past Antibodies
Patients with inflammatory bowel disease saw sustained clinical responses after switching to a subcutaneous form of infliximab.
Updated on Oct. 13, 2026 in Diabetes
Live Poll
Do you trust that new medical therapies can be effective despite a history of drug reactions?
A post hoc analysis found that anti-drug antibodies did not impair clinical outcomes for patients with Crohn disease or ulcerative colitis who transitioned to subcutaneous infliximab. This research offers new data for those managing inflammatory bowel disease after a treatment holiday.
Why it matters
This finding clarifies that prior antibody development against intravenous infliximab may not prevent success with the subcutaneous version of the drug. It provides a potential path for patients to regain therapeutic control when switching treatment delivery methods after a break.
This analysis reviewed 128 patients, finding that clinical response was achieved within 8 weeks of subcutaneous treatment and sustained for up to 80 weeks. While positive antibody status was common at initiation, serum drug concentrations rose and antibody positivity declined during treatment.
The players
American College of Gastroenterology
A professional medical organization that promotes the study and clinical care of gastrointestinal health and digestive diseases.
The details
Patients in these trials were initially treated with intravenous infliximab before transitioning to a 240 mg subcutaneous dose. The analysis evaluated patients who had developed anti-drug antibodies following a median 16-week gap between treatment forms. Researchers found that subcutaneous administration effectively bypassed the inhibitory effects previously seen, as indicated by rising serum drug levels and sustained clinical remission throughout the study period.
Timeline
October 2023: The FDA approved subcutaneous infliximab for maintenance treatment.
October 9-14, 2026: The American College of Gastroenterology Annual Scientific Meeting took place in Nashville.
Health Landscape
These findings build upon the framework established by the LIBERTY-CD and LIBERTY-UC clinical trials to define long-term efficacy. The results suggest a shift in how clinicians may view the durability of biologic therapies for inflammatory bowel disease following a treatment gap.
If you have a history of developing anti-drug antibodies with previous treatments, these results are worth discussing with your gastroenterologist regarding your current management plan. Ask your physician if this research changes your eligibility for subcutaneous therapy options.
The takeaway
Prior anti-drug antibodies do not necessarily preclude success when initiating subcutaneous infliximab. Consider tracking your clinical response and discussing serum concentration monitoring with your doctor if you are restarting a biologic therapy after an interval.
Further reading
For broader context on managing chronic conditions, explore our Diabetes section.
Source note: This article includes information reported by Hcplive.
Live Poll
Do you trust that new medical therapies can be effective despite a history of drug reactions?
